Prothena EBITDA 2011-2022 | PRTA

Prothena ebitda from 2011 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Prothena Annual EBITDA
(Millions of US $)
2021 $79
2020 $-106
2019 $-79
2018 $-156
2017 $-152
2016 $-157
2015 $-79
2014 $-6
2013 $-40
2012 $-41
2011 $-29
2010 $-12
Prothena Quarterly EBITDA
(Millions of US $)
2022-03-31 $-36
2021-12-31 $-31
2021-09-30 $111
2021-06-30 $30
2021-03-31 $-30
2020-12-31 $-29
2020-09-30 $-29
2020-06-30 $-25
2020-03-31 $-23
2019-12-31 $-22
2019-09-30 $-19
2019-06-30 $-17
2019-03-31 $-21
2018-12-31 $-22
2018-09-30 $-24
2018-06-30 $-62
2018-03-31 $-48
2017-12-31 $-47
2017-09-30 $-53
2017-06-30 $-17
2017-03-31 $-36
2016-12-31 $-48
2016-09-30 $-42
2016-06-30 $-40
2016-03-31 $-27
2015-12-31 $-24
2015-09-30 $-22
2015-06-30 $-18
2015-03-31 $-15
2014-12-31 $-13
2014-09-30 $-13
2014-06-30 $2
2014-03-31 $18
2013-12-31 $-10
2013-09-30 $-9
2013-06-30 $-11
2013-03-31 $-9
2012-12-31 $-12
2012-09-30 $-9
2012-06-30 $-10
2012-03-31 $-11
2011-12-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.215B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00